JP2823170B2 - 溶解率を向上した担体支持薬剤およびその製造方法 - Google Patents

溶解率を向上した担体支持薬剤およびその製造方法

Info

Publication number
JP2823170B2
JP2823170B2 JP1308833A JP30883389A JP2823170B2 JP 2823170 B2 JP2823170 B2 JP 2823170B2 JP 1308833 A JP1308833 A JP 1308833A JP 30883389 A JP30883389 A JP 30883389A JP 2823170 B2 JP2823170 B2 JP 2823170B2
Authority
JP
Japan
Prior art keywords
carrier
drug
crospovidone
cyclodextrin
weight ratio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP1308833A
Other languages
English (en)
Japanese (ja)
Other versions
JPH02184621A (ja
Inventor
ルシア ロブレシッチ マラ
Original Assignee
ヴェクトォアファーマ インターナショナル エス．ピィ．エイ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴェクトォアファーマ インターナショナル エス．ピィ．エイ． filed Critical ヴェクトォアファーマ インターナショナル エス．ピィ．エイ．
Publication of JPH02184621A publication Critical patent/JPH02184621A/ja
Application granted granted Critical
Publication of JP2823170B2 publication Critical patent/JP2823170B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y10S977/798—Lipid particle having internalized material
    • Y10S977/799—Containing biological material
    • Y10S977/801—Drug
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Electroluminescent Light Sources (AREA)
  • Control Of El Displays (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Steroid Compounds (AREA)
JP1308833A 1988-11-28 1989-11-28 溶解率を向上した担体支持薬剤およびその製造方法 Expired - Fee Related JP2823170B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT8822770A IT1227626B (it) 1988-11-28 1988-11-28 Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
IT22770A/88 1988-11-28

Publications (2)

Publication Number Publication Date
JPH02184621A JPH02184621A (ja) 1990-07-19
JP2823170B2 true JP2823170B2 (ja) 1998-11-11

Family

ID=11200272

Family Applications (1)

Application Number Title Priority Date Filing Date
JP1308833A Expired - Fee Related JP2823170B2 (ja) 1988-11-28 1989-11-28 溶解率を向上した担体支持薬剤およびその製造方法

Country Status (16)

Country Link
US (2) US5354560A (he)
EP (1) EP0371431B1 (he)
JP (1) JP2823170B2 (he)
KR (1) KR900007398A (he)
AT (1) ATE123940T1 (he)
CA (1) CA2004064C (he)
DE (1) DE68923157T2 (he)
DK (1) DK175684B1 (he)
ES (1) ES2076192T3 (he)
FI (1) FI895693A0 (he)
HU (1) HU203468B (he)
IL (1) IL92454A (he)
IT (1) IT1227626B (he)
PT (1) PT92416B (he)
RU (2) RU1837868C (he)
YU (1) YU221189A (he)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5569469A (en) * 1984-10-16 1996-10-29 Vectorpharma International, S.P.A. Poorly soluble medicaments supported on polymer substances in a form suitable for increasing their dissolving rate
IT1241088B (it) * 1990-03-27 1993-12-29 Chiesi Farma Spa Procedimento per la preparazione di complessi piroxicam/ciclodestrina,prodotti ottenuti e loro composizioni farmaceutiche
HU210921B (en) * 1990-03-28 1995-09-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them
IT1246188B (it) * 1990-07-27 1994-11-16 Resa Farma Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute.
IT1243745B (it) * 1990-10-17 1994-06-21 Vectorpharma Int Composizioni terapeutiche transdermali contenenti farmaco e/o agente promotore dell'assorbimento cutaneo supportato su particelle microporose e microsfere polimeriche e loro preparazione.
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
DE69231457T2 (de) * 1991-06-21 2001-05-23 Takeda Chemical Industries Ltd Zyklodextrin-Zusammensetzung enthaltend Fumagillol-Derivate
EP0644755B1 (en) * 1992-06-10 1997-03-19 NanoSystems L.L.C. Surface modified nsaid nanoparticles
IT1255462B (it) * 1992-07-28 1995-11-02 Grazia Maffione Metodo di preparazione di composti di inclusione di nimesulide con ciclodestrine
AU660852B2 (en) * 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
HU213200B (en) 1993-05-12 1997-03-28 Chinoin Gyogyszer Es Vegyeszet The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production
GB9316580D0 (en) * 1993-08-10 1993-09-29 Smithkline Beecham Plc Pharmaceutical composition
TW384224B (en) * 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5684121A (en) * 1994-12-06 1997-11-04 Isp Investments Inc. N-vinyl lactam polymer containing tablets of low friability and high rate of dissolution
US5759577A (en) * 1995-01-17 1998-06-02 American Home Products Corporation Controlled release of steroids from sugar coatings
US5547948A (en) * 1995-01-17 1996-08-20 American Home Products Corporation Controlled release of steroids from sugar coatings
US5518738A (en) * 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5612053A (en) 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US6348469B1 (en) 1995-04-14 2002-02-19 Pharma Pass Llc Solid compositions containing glipizide and polyethylene oxide
PT822808E (pt) * 1995-04-20 2000-12-29 Eurand Int Composito com glicolato de amido e sodio como material de suporte e produtos seus derivados
US20050267302A1 (en) * 1995-12-11 2005-12-01 G.D. Searle & Co. Eplerenone crystalline form exhibiting enhanced dissolution rate
US5686133A (en) * 1996-01-31 1997-11-11 Port Systems, L.L.C. Water soluble pharmaceutical coating and method for producing coated pharmaceuticals
HUP9600758A2 (en) * 1996-03-27 1998-03-02 Cyclolab Ciklodextrin Kutato F Diclofenac composition of diminished gastrointestinal irritation and enhanced biological resorption
US6048547A (en) * 1996-04-15 2000-04-11 Seth; Pawan Process for manufacturing solid compositions containing polyethylene oxide and an active ingredient
WO1997039761A1 (en) 1996-04-19 1997-10-30 Alpha Therapeutic Corporation A process for viral inactivation of lyophilized blood proteins
FR2757397B1 (fr) * 1996-12-23 1999-03-05 Mazal Pharma Composition pharmaceutique a base de rheine ou de diacerheine a biodisponibilite amelioree
US20050004049A1 (en) * 1997-03-11 2005-01-06 Elan Pharma International Limited Novel griseofulvin compositions
US6451771B1 (en) 1999-02-12 2002-09-17 Nutramax Laboratories, Inc. Use of anabolic agents anti-catabolic agents and antioxidant agents for protection treatment and repair of connective tissues in humans and animals
US6797289B2 (en) 1998-02-13 2004-09-28 Nutramax Laboratories, Inc. Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
US20070141181A1 (en) * 1998-02-13 2007-06-21 Nutramax Laboratories, Inc. Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
US6086242A (en) * 1998-02-27 2000-07-11 University Of Utah Dual drive planetary mill
US6197347B1 (en) 1998-06-29 2001-03-06 Andrx Pharmaceuticals, Inc. Oral dosage for the controlled release of analgesic
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
FR2786100B1 (fr) * 1998-11-24 2002-03-01 Aventis Laboratoire Nouvelle application therapeutique de la nicergoline
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
UA74539C2 (en) 1999-12-08 2006-01-16 Pharmacia Corp Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
AU784490B2 (en) * 1999-12-08 2006-04-13 Pharmacia Corporation Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
CN100413881C (zh) * 1999-12-08 2008-08-27 法马西亚公司 依匹乐酮晶形
US20030083493A1 (en) * 1999-12-08 2003-05-01 Barton Kathleen P. Eplerenone drug substance having high phase purity
US20060153914A1 (en) * 1999-12-10 2006-07-13 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
AR035642A1 (es) * 2000-05-26 2004-06-23 Pharmacia Corp Uso de una composicion de celecoxib para el alivio rapido del dolor
US20020146409A1 (en) * 2001-01-30 2002-10-10 Herring Steven W. Methods for stabilizing lyophilized blood proteins
NZ530227A (en) * 2001-06-18 2006-09-29 Noven Pharma Enhanced drug delivery in transdermal systems
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
HUP0400281A3 (en) * 2001-06-22 2009-11-30 Pfizer Prod Inc Pharmaceutical compositions of adsorbates of amorphous drug and process for their preparation
DE60223382T2 (de) * 2001-06-29 2008-09-11 Eurand Pharmaceuticals Ltd., Bray Verfahren für die thermodynamische aktivierung von wasserlöslichen arzneimitteln, die in vernetzten polymeren geladen sind
US20030073609A1 (en) 2001-06-29 2003-04-17 Pinkerton Thomas C. Enhanced pharmacokinetic profile of intradermally delivered substances
JP2005529060A (ja) * 2001-09-25 2005-09-29 ファルマシア コーポレイション Ｎ−（２−ヒドロキシアセチル）−５−（４−ピペリヂル）−４−（４−ピリミヂニル）−３−（４−クロロフェニル）ピラゾールの固体形態
JP2005523262A (ja) 2002-02-01 2005-08-04 ファイザー・プロダクツ・インク 薬物及び親油性ミクロ相形成物質の非晶質分散物の医薬組成物
US9101540B2 (en) * 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US20100226989A1 (en) * 2002-04-12 2010-09-09 Elan Pharma International, Limited Nanoparticulate megestrol formulations
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
US7101576B2 (en) 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
EP2263650A3 (en) * 2002-04-12 2013-12-25 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
ITMI20021074A1 (it) * 2002-05-20 2003-11-20 Actimex S R L Composizione ternaria comprendente una sostanza attiva e processo di comacinazione per la sua preparazione
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
DE10259640A1 (de) * 2002-12-18 2004-07-08 Hager & Werken Gmbh & Co Kg Einfärbemittel zur Sichtbarmachung von Plaque-Bildung auf Zähnen sowie Verfahren zur Herstellung eines solchen Einfärbemittels
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
EP2343045A3 (en) * 2003-02-24 2011-09-21 Pharmaceutical Productions Inc. Transmucosal drug delivery system
US9254294B2 (en) 2003-02-24 2016-02-09 Pharmaceutical Productions Inc. Transmucosal hormone delivery system
US9358296B2 (en) 2003-02-24 2016-06-07 Pharmaceutical Productions Inc. Transmucosal drug delivery system
US9498454B2 (en) 2003-02-24 2016-11-22 Pharmaceutical Productions Inc. Transmucosal drug delivery system
US10172810B2 (en) 2003-02-24 2019-01-08 Pharmaceutical Productions, Inc. Transmucosal ketamine delivery composition
PT1638527E (pt) * 2003-06-27 2007-02-28 Bioprogress Spa Produto compósito obtido por co-trituração de um princípio activo com um copolímero de n-vinil-2-pirrolidona/acetato de vinilo
DE602004000260T2 (de) 2003-07-22 2006-08-24 Arena Pharmaceuticals, Inc., San Diego Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
MXPA06001417A (es) 2003-08-04 2006-05-15 Pfizer Prod Inc Composiciones farmaceuticas de adsorbatos de farmacos amorfos y materiales que forman microfases lipofilas.
WO2007002315A2 (en) * 2005-06-22 2007-01-04 Elan Pharma International, Limited Nanoparticulate megestrol formulations
EP2003970A4 (en) * 2006-03-28 2012-07-11 Javelin Pharmaceuticals Inc FORMULATIONS OF NON-STEROID ANTI-INFLAMMATORY DRUGS WITH LOW DOSE AND BETA-CYCLODEXTRIN
MX2008012495A (es) 2006-03-28 2009-01-07 Javelin Pharmaceuticals Inc Formulaciones de dosis baja de diclofenaco y beta-ciclodextrina.
WO2008000042A1 (en) * 2006-06-30 2008-01-03 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
AU2016203251B2 (en) * 2006-06-30 2017-11-16 Iceutica Pty Ltd Methods for the Preparation of Biologically Active Compounds in Nanoparticle Form
CL2007002689A1 (es) 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
JP5393677B2 (ja) 2007-08-15 2014-01-22 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ＨＴ２Ａセロトニン受容体に関連した障害の治療のための５−ＨＴ２Ａセロトニン受容体のモジュレーターとしてのイミダゾ［１，２−ａ］ピリジン誘導体
US8821924B2 (en) 2007-09-14 2014-09-02 Wockhardt Ltd. Rhein or diacerein compositions
EP2520284A1 (en) * 2007-09-27 2012-11-07 Wockhardt Limited Pharmaceutical compositions of rhein or diacerein
US20100285114A1 (en) * 2007-09-27 2010-11-11 Rahul Dabre Pharmaceutical compositions of rhein or diacerein
WO2009048940A2 (en) * 2007-10-08 2009-04-16 Dr. Reddy's Laboratories Ltd. Diacerein pharmaceutical formulations
US8642062B2 (en) 2007-10-31 2014-02-04 Abbott Cardiovascular Systems Inc. Implantable device having a slow dissolving polymer
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
HUE036506T2 (hu) 2008-10-28 2018-07-30 Arena Pharm Inc 5-HT2A szerotonin receptor modulátort tartalmazó készítmények az ilyen receptor modulátorokkal kapcsolatos rendellenességek kezelésére
US8778401B2 (en) * 2008-10-28 2014-07-15 Agency For Science, Technology And Research Mesoporous material excipients for poorly aqueous soluble ingredients
US7828996B1 (en) 2009-03-27 2010-11-09 Abbott Cardiovascular Systems Inc. Method for the manufacture of stable, nano-sized particles
SG175315A1 (en) 2009-04-24 2011-11-28 Iceutica Pty Ltd A novel formulation of indomethacin
WO2010148158A1 (en) * 2009-06-17 2010-12-23 Isp Investments Inc. A process for preparation of stable, microencapsulated and sustained release biocidal actives and composition thereof
AR077692A1 (es) 2009-08-06 2011-09-14 Vitae Pharmaceuticals Inc Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
JP5870775B2 (ja) * 2011-05-11 2016-03-01 ライオン株式会社 錠剤及びその製造方法
EP2734204A4 (en) 2011-07-22 2015-03-18 Chemocentryx Inc POLYMORPHIC FORMS OF 4-TERT-BUTYL-N- [4-CHLORO-2- (1-OXY-PYRIDINE-4-CARBONYL) -PHENYL] -BENZENE-SULFONAMIDE SODIUM SALT
US9133124B2 (en) 2011-07-22 2015-09-15 Chemocentryx, Inc. Crystalline form of the sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide
KR101378951B1 (ko) * 2011-07-29 2014-03-31 재단법인 유타 인하 디디에스 및 신의료기술개발 공동연구소 생체이용률이 향상된 초산 메게스트롤 분말을 포함하는 경구투여용 제제 및 이의 제조방법
PL2751094T3 (pl) 2011-09-01 2018-11-30 Glaxo Group Limited Nowa postać krystaliczna
KR20130025851A (ko) * 2011-09-02 2013-03-12 재단법인 유타 인하 디디에스 및 신의료기술개발 공동연구소 메게스트롤 속붕해정 및 이의 제조 방법
WO2013095318A2 (en) * 2011-12-23 2013-06-27 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Orally-disintegrating formulations of flurbiprofen
WO2013100881A2 (en) * 2011-12-27 2013-07-04 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Combined pharmaceutical formulation containing diacerein
ITMI20120092A1 (it) 2012-01-26 2013-07-27 Micro Macinazione S A Compositi di inclusione farmaco-carrier preparati con processo di attivazione meccano-chimica mediante mulini a getto di fluido ad alta energia
ES2821528T3 (es) 2012-11-14 2021-04-26 Grace W R & Co Composiciones que contienen un material biológicamente activo y un óxido inorgánico no ordenado
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
SG11201610709UA (en) 2014-06-25 2017-01-27 Glaxosmithkline Ip Dev Ltd Crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide
AU2015313894A1 (en) 2014-09-08 2017-03-23 Glaxosmithkline Intellectual Property Development Limited Crystalline forms of 2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophenyl)-n-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)acetamide
MX2017016413A (es) 2015-06-12 2018-08-01 Axovant Sciences Gmbh Derivados de diaril y arilheteroaril urea como moduladores del receptor 5ht2a de serotonina útiles para la profilaxis y el tratamineto de un trastorno conductual del sueño rem.
JP2018520187A (ja) 2015-07-15 2018-07-26 アクソヴァント サイエンシーズ ゲゼルシャフト ミット ベシュレンクテル ハフツングAxovant Sciences GmbH 神経変性疾患と関連する幻覚の予防および処置のために有用な５−ｈｔ２ａセロトニン受容体のモジュレーターとしてのジアリールおよびアリールヘテロアリール尿素誘導体

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3079303A (en) * 1958-12-11 1963-02-26 Smith Kline French Lab Basic tablet granulation and process of using same
NO98434A (he) * 1959-04-30
US3328256A (en) * 1963-05-27 1967-06-27 William E Gaunt Spherical beads and their production
NL6414091A (nl) * 1964-12-04 1966-06-06 Organon Nv Werkwijze voor het vloeibaar maken van poeders alsmede de aldus verkregen poeders
JPS5132719A (en) * 1974-09-13 1976-03-19 Yoshinobu Nakai Iyakuhinnoshorihoho
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US4037794A (en) * 1974-09-23 1977-07-26 Dierks & Sohne Granulation apparatus
DE2742442C3 (de) * 1977-09-21 1980-03-06 Balcke-Duerr Ag, 4030 Ratingen Elastische Kupplung
JPS5849428A (ja) * 1981-09-16 1983-03-23 Takeda Chem Ind Ltd 細粒剤の製造法
EP0129893B1 (en) * 1983-06-28 1991-09-04 Takeda Chemical Industries, Ltd. Ground mixture
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
GB8403359D0 (en) * 1984-02-08 1984-03-14 Erba Farmitalia Pharmaceutical compositions
US4837031A (en) * 1987-09-17 1989-06-06 Mallinckrodt, Inc. Compositions containing ibuprofen

Also Published As

Publication number Publication date
RU2097027C1 (ru) 1997-11-27
DE68923157D1 (de) 1995-07-27
ATE123940T1 (de) 1995-07-15
EP0371431A3 (en) 1991-10-09
RU1837868C (ru) 1993-08-30
US5354560A (en) 1994-10-11
IT8822770A0 (it) 1988-11-28
US5449521A (en) 1995-09-12
EP0371431B1 (en) 1995-06-21
EP0371431A2 (en) 1990-06-06
IL92454A0 (en) 1990-08-31
HU896191D0 (en) 1990-02-28
HU203468B (en) 1991-08-28
PT92416A (pt) 1990-05-31
PT92416B (pt) 1995-08-09
CA2004064C (en) 2000-02-08
DE68923157T2 (de) 1995-11-09
IL92454A (he) 1994-06-24
KR900007398A (ko) 1990-06-01
JPH02184621A (ja) 1990-07-19
HUT52366A (en) 1990-07-28
DK595889A (da) 1990-05-29
DK175684B1 (da) 2005-01-17
CA2004064A1 (en) 1990-05-28
FI895693A0 (fi) 1989-11-28
DK595889D0 (da) 1989-11-27
ES2076192T3 (es) 1995-11-01
IT1227626B (it) 1991-04-23
YU221189A (en) 1991-06-30

Similar Documents

Publication Publication Date Title
JP2823170B2 (ja) 溶解率を向上した担体支持薬剤およびその製造方法
El-Badry et al. Improvement of solubility and dissolution rate of indomethacin by solid dispersions in Gelucire 50/13 and PEG4000
CA2022465C (en) Process for micronizing slightly-soluble drug
Fernandes et al. A review on solubility enhancement of carvedilol—a BCS class II drug
Pawar et al. Development of amorphous dispersions of artemether with hydrophilic polymers via spray drying: Physicochemical and in silico studies
GB2153678A (en) Pharmaceutical composition
JPH05262642A (ja) 難溶性薬物の固体分散体の製造方法
JP2010526848A (ja) 難溶性薬物用の医薬組成物
US5164380A (en) Process for preparing piroxicam/cyclodextrin complexes, the products obtained and their pharmaceutical compositions
KR0148006B1 (ko) 용해속도를 증가시키기에 적합한 형태로 중합체 기재로 지지된 저가용성약제 및 이의 제조방법
US20090012284A1 (en) Process for the Preparation of a Piroxicam: Betacyclodextrin Inclusion Compound
Zhang et al. Preparation, characterization, in vitro and in vivo studies of olmesartan medoxomil in a ternary solid dispersion with N-methyl-D-glucamine and hydroxypropyl-β-cyclodextrin
JP2948886B2 (ja) 改良された溶解特性を有する医薬組成物
JPS60181017A (ja) Ｍａｐ固体状製剤およびその製造方法
JPH11503749A (ja) 支持剤であるデンプングリコール酸ナトリウムとの複合物およびその製品
Acerbi et al. Biopharmaceutical optimisation of β-cyclodextrin inclusion compounds
Magdum Liquisolid technique for dissolution and bioavailability enhancement of poorly soluble drugs
Moyano et al. Evaluation of dissolution characteristics of oxazepam-2-hydroxypropyl-β-cyclodextrin binary systems
WO2024153733A1 (en) Crystalline nanoparticles comprising enzalutamide
Ghalan et al. Review on Manufacturing Methods of Solid Dispersion Technology for Enhancing the Solubility of Poorly Water-Soluble Drugs
Jadhav et al. Enhancement of solubility and dissolution rate of griseofulvin by microparticulate systems
Thakare The evaluation of larch arabinogalactan as a new carrier in the formulation of solid dispersions of poorly water-soluble drugs
Jadhav et al. Preparation and Evaluation of Microwave Generated Nanocomposites for Solubility Enhancement of Ketoprofen
Hamed et al. Preparation and In-Vitro, Ex-Vivo Evaluation of Oral Dosage Form Containing Mirtazapine Nano suspension
Williams III et al. Preparation of drug particles using evaporation precipitation into aqueous solutions

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees